What Happened

Travere Therapeutics presented long-term open-label extension data from the Phase 3 DUPLEX Study at the 2026 European Renal Association Congress. The study demonstrated FILSPARI's sustained efficacy in reducing proteinuria in FSGS patients over five years, including those transitioning from irbesartan.

Who Is Affected

Nephrologists, renal care providers, and FSGS patients are directly impacted. FILSPARI's long-term efficacy and safety data make it a compelling treatment option for managing FSGS without nephrotic syndrome.

Market Impact

• FILSPARI solidifies its position as foundational care for FSGS.
• Providers may shift treatment protocols to prioritize FILSPARI over irbesartan.
• Travere Therapeutics gains credibility in the nephrology market.

What to Watch

Monitor adoption rates of FILSPARI among nephrologists and renal care providers. Watch for further clinical data and real-world evidence supporting its long-term benefits in FSGS treatment.